OBCK Ottobock SE & Co. KGaA

41.44USD37.70 EUR · XETRA-1.18%Mkt Cap: 2.65B USDP/E: 18.57

Ottobock SE & Co. KGaA develops, produces, and distributes medical technology products and components for the people with disabilities in the fields of prosthetics, orthotics, human mobility, and industrial exoskeletons …

Key Statistics

Company
Market Cap2.65B USD
Enterprise Value3.92B USD
Revenue (TTM)1.95B USD
Gross Profit974.44M USD
Net Income (TTM)99.15M USD
Revenue/Share30.80 USD
Last Price41.44 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees9.5K
CountryDE
SectorHealthcare
IndustryMedical Instruments & Supplies
ISINDE000BCK2223
Valuation
P/E (Trailing)18.57
P/E (Forward)10.61
PEG—
EV/EBITDA9.62
EV/Revenue2.02
P/S1.36
P/B5.34
EPS (TTM)2.23 USD
EPS (Forward)3.91 USD
52W Range
41.221% of range83.92
52W High83.92 USD
52W Low41.22 USD
Profitability
Gross Margin52.77%
Oper. Margin18.70%
EBITDA Margin20.97%
Profit Margin5.37%
ROE23.12%
ROA4.40%
ROIC10.30%
ROCE16.87%
Growth
Revenue Growth8.80%
Earnings Growth82.90%
Cash Flow & Leverage
Operating CF366.25M USD
CapEx (TTM)119.48M USD
FCF Margin5.73%
FCF Yield4.20%
Net Debt1.26B USD
Net Debt/EBITDA3.09
Net Debt/FCF11.32
Balance Sheet
Debt/Equity2.69
Current Ratio1.28
Quick Ratio0.66
Book Value/Sh7.76 USD
Cash/Share1.70 USD
Dividends
Fwd Div Rate1.07 USD
Trail. Div Rate1.07 USD
Div. Yield2.57%
5Y Avg Yield—
Payout Ratio41.70%
Ex-Div DateMay 20, 2026
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)79.42 USD
Upside (mean)+91.6%
Target Range59.36 USD – 94.53 USD
59.36+91.6% to mean94.53
# Analysts8
Ownership
Shares Out.63.99M
Float9.04M
Insiders82.44%
Institutions11.58%
Technical
SMA 5055.46 (-25.3%)
SMA 20059.72 (-30.6%)
Beta—
S&P 52W Chg8.68%
Avg Vol (30d)61.19K
Avg Vol (10d)110.92K
Technical Indicators
RSI (14)19.1
MACD-3.6157
MACD Signal-2.9018
MACD Hist.-0.7138
BB Upper59.35 USD
BB Middle49.13 USD
BB Lower38.91 USD
BB Width41.62%
ATR (14)2.027 USD
Vol Ratio (20d)0.67x

About Ottobock (ETR: OBCK)

›

Ottobock (ETR: OBCK) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 9,455 employees.

The shares were at 37.70 EUR on 20 November 2026, down 45.8% over 52 weeks. Its 52-week range is 37.50 EUR to 76.35 EUR, and it trades at the bottom of that range.

At a market capitalisation of 2.41B EUR, it trades at 18.6 times trailing earnings and 10.6 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 48.3, a discount of 62% for OBCK. It pays a dividend yielding 2.57% (it pays out 42% of its earnings), against a median of 0.92% among the dividend payers in that peer group.

Ottobock reports return on equity of 23.1%, an operating margin of 18.7% and revenue up 8.8% year over year.

Its debt exceeds its cash by 1.15B EUR, a debt-to-equity ratio of 2.69. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 72.25 EUR is 91.6% above the current price. The next earnings report is expected on 11 March 2027.